Please login (Members) to view content or
(Nonmembers) this article.
0
No votes yet

Antiangiogenesis: The Fifth Cancer Treatment Modality?

Dawn Camp-Sorrell
ONF 2003, 30(6), 934-944 DOI: 10.1188/03.ONF.934-944

Purpose/Objectives: To describe the biologic process of angiogenesis and the potential role of antiangiogenesis therapy in cancer treatment.

Data Sources: Published articles, conference proceedings, and computerized databases.

Data Synthesis: Angiogenesis is the development of blood vessels. Antiangiogenic agents prevent the development of blood vessels, therefore preventing one mode of cancer metastasis. Clinical trials must be conducted to ascertain the most powerful antiangiogenic therapies. Trials combine chemotherapy, biotherapy, and radiotherapy with antiangiogenic therapy.

Conclusions: Information from animal studies has revealed that antiangiogenesis is a viable option in treating cancer and preventing metastasis. Although human studies are rare, preliminary results are promising, especially when antiangiogenesis is used in combination with current cancer treatment modalities.

Implications for Nursing: Nurses are in a unique position to teach patients about new treatments for cancer. Nurses must be knowledgeable about angiogenesis and the availability of potential antiangiogenesis agents. Nurses will be vital in collecting data in clinical trials, considering the subjective data that will be obtained.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or